Aribio Holdings, Aribio, and Aribio Lab are embarking on a comprehensive "full-cycle value chain" to prevent, treat, and manage degenerative brain diseases.
On October 1, the Aribio Group held a "2026 Vision Declaration Ceremony" at Dragon City in Seoul, where they announced a growth roadmap centered around Aribio Holdings. Chairman Jeong Jae-jun stated, "Dementia progresses over more than 20 years, from asymptomatic stages to mild cognitive impairment and severe dementia, necessitating an integrated solution throughout the entire cycle. We will take responsibility for the entire cycle of brain diseases through a unified platform connecting Aribio Lab (prevention), Aribio (treatment), and Aribio Holdings (management)."
The core of the group’s strategy is the oral dementia treatment candidate AR1001. A total of 1,535 participants were enrolled in a global Phase 3 clinical trial conducted across 230 institutions in 13 countries, with 1,348 completing 52 weeks of treatment. The company plans to present topline results at the Clinical Trials on Alzheimer’s Disease (CTAD 2026) conference in Boston on November 16 and aims to initiate the U.S. Food and Drug Administration (FDA) approval process in 2027-2028.
Aribio has also signed commercialization agreements with companies like Samjin Pharmaceutical across five regions. With the Alzheimer’s market valued at approximately $18.5 billion, the company aims to expand its indications to include stroke ($19.5 billion), Parkinson’s disease ($7.5 billion), and vascular dementia ($7.5 billion), targeting $8.5 billion in revenue by 2030. The treatment for Lewy body dementia, AR1005, is expected to yield Phase 2 results in 2027, while the treatment for mild cognitive impairment, AR1004, has received approval for its Phase 2 trial.
Aribio Lab will focus on "prevention." Leveraging its proprietary immune-enhancing platform, the company is developing a shingles vaccine (currently in Phase 2) and a hepatitis B vaccine. Inspired by recent research indicating that shingles vaccination reduces dementia risk, Aribio Lab plans to expand into Alzheimer’s vaccine development, with preclinical studies set to begin in 2026-2027 and commercialization anticipated post-2030. To support this initiative, the company has recruited international experts, including Professor Anthony Cunningham, who led the Phase 3 trials for GlaxoSmithKline’s shingles vaccine Shingrix, as scientific advisors.
Aribio Holdings will oversee the group’s investments and "management." The company plans to reinvest cash generated from its core business into biopharmaceutical development while expanding its brain health management initiatives, including an AI data center business and the sale of vibration-based electronic medicine, Herzion. The data center project is set to evolve into an AI infrastructure that integrates the group’s research and clinical data. The company aims to increase revenue to between $170 million and $255 million in 2027-2028 and to $255 million to $425 million in 2029-2030.
Chairman Jeong remarked, "The Phase 3 results announcement in November will be a significant milestone for the group’s direction. We will challenge not only degenerative brain diseases like dementia and Parkinson’s but also issues related to aging."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.